Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Pharmacogenet Genomics. 2013 Dec;23(12):697–705. doi: 10.1097/FPC.0000000000000012

Figure 1.

Figure 1

CF7L2 SNP*HCTZ treatment interactions in INVEST whites, including significant SNPs after PACT correction and nominally significant SNPs that have been previously associated with T2D or T2D-related traits. Odds ratios, 95% confidence intervals, and interaction p values adjusted for age, gender, body mass index, average on treatment systolic blood pressure, hypercholesterolemia, history of smoking, principal components one, two, and three, trandolapril and atenolol treatment, and trandolapril, atenolol, and HCTZ treatment duration. Superscript letters indicate that SNPs are in linkage disequilibrium (r2>0.80); *Allele previously associated with T2D or T2D-related traits. HCTZ indicates hydrochlorothiazide; NOD, new onset diabetes; SNP, single nucleotide polymorphism.